Stribild Tablet, Film Coated
NDC Package 61958-1201-1
Package Information
Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) tablets is sTRIBILD® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of STRIBILD [see Clinical Studies (14)]. This formulation utilizes a tablet, film coated delivery system. Marketed by Gilead Sciences, Inc., this product is identified by NDC 61958-1201 and is authorized under FDA application NDA203100.
Identification & Billing
- RxCUI: 1306292 - elvitegravir 150 MG / cobicistat 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
- RxCUI: 1306292 - cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
- RxCUI: 1306292 - cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG) Oral Tablet
- RxCUI: 1306298 - Stribild 150 MG / 150 MG / 200 MG / 300 MG Oral Tablet
- RxCUI: 1306298 - cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Stribild]
Clinical Specifications
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2C9 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2D6 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitor - [EPC] (Established Pharmacologic Class)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- HIV Integrase Inhibitors - [MoA] (Mechanism of Action)
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors - [MoA] (Mechanism of Action)
- Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
- Nucleosides - [CS]
- Organic Anion Transporting Polypeptide 1B1 Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporting Polypeptide 1B3 Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 61958 - Gilead Sciences, Inc.
- 61958-1201 - Stribild
- 61958-1201-1 - 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
- 61958-1201 - Stribild
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61958-1201-1 identifies a specific commercial package of 30 tablet, film coated in 1 bottle, plastic of Stribild, a human prescription drug labeled by Gilead Sciences, Inc.. This tablet, film coated is formulated for oral use and contains elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gilead Sciences, Inc. on August 27, 2012. The current certification is valid through December 31, 2026.
How is this Gilead Sciences, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61958120101. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.